JP2021501763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501763A5 JP2021501763A5 JP2020524388A JP2020524388A JP2021501763A5 JP 2021501763 A5 JP2021501763 A5 JP 2021501763A5 JP 2020524388 A JP2020524388 A JP 2020524388A JP 2020524388 A JP2020524388 A JP 2020524388A JP 2021501763 A5 JP2021501763 A5 JP 2021501763A5
- Authority
- JP
- Japan
- Prior art keywords
- peanut
- level
- specific ige
- subject
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000017060 Arachis glabrata Nutrition 0.000 claims 73
- 241001553178 Arachis glabrata Species 0.000 claims 73
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 73
- 235000018262 Arachis monticola Nutrition 0.000 claims 73
- 235000020232 peanut Nutrition 0.000 claims 73
- 238000000034 method Methods 0.000 claims 71
- 239000000203 mixture Substances 0.000 claims 37
- 230000002009 allergenic effect Effects 0.000 claims 16
- 208000008267 Peanut Hypersensitivity Diseases 0.000 claims 12
- 206010016946 Food allergy Diseases 0.000 claims 11
- 206010020751 Hypersensitivity Diseases 0.000 claims 11
- 201000010853 peanut allergy Diseases 0.000 claims 11
- 238000009169 immunotherapy Methods 0.000 claims 10
- 230000003111 delayed effect Effects 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 7
- 229930182837 (R)-adrenaline Natural products 0.000 claims 7
- 229960005139 epinephrine Drugs 0.000 claims 7
- 208000030961 allergic reaction Diseases 0.000 claims 6
- 238000012544 monitoring process Methods 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000036387 respiratory rate Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000004448 titration Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580999P | 2017-11-02 | 2017-11-02 | |
| US62/580,999 | 2017-11-02 | ||
| US201862631406P | 2018-02-15 | 2018-02-15 | |
| US62/631,406 | 2018-02-15 | ||
| US201862637903P | 2018-03-02 | 2018-03-02 | |
| US62/637,903 | 2018-03-02 | ||
| US201862674478P | 2018-05-21 | 2018-05-21 | |
| US62/674,478 | 2018-05-21 | ||
| PCT/US2018/058777 WO2019089978A1 (en) | 2017-11-02 | 2018-11-01 | Methods of oral immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501763A JP2021501763A (ja) | 2021-01-21 |
| JP2021501763A5 true JP2021501763A5 (https=) | 2021-12-09 |
| JP7498661B2 JP7498661B2 (ja) | 2024-06-12 |
Family
ID=66332382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524388A Active JP7498661B2 (ja) | 2017-11-02 | 2018-11-01 | 経口免疫療法の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11369676B2 (https=) |
| EP (1) | EP3703743A4 (https=) |
| JP (1) | JP7498661B2 (https=) |
| KR (1) | KR102753602B1 (https=) |
| CN (1) | CN111344010A (https=) |
| AU (1) | AU2018358125B2 (https=) |
| CA (1) | CA3080601A1 (https=) |
| MX (1) | MX2020004683A (https=) |
| WO (1) | WO2019089978A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| WO2014159607A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
| AU2015306683B2 (en) | 2014-08-25 | 2021-11-25 | Societe Des Produits Nestle S.A. | Egg protein formulations and methods of manufacture thereof |
| EP4545077A1 (en) | 2017-12-06 | 2025-04-30 | Prollergy Corporation | Composition and method for reducing allergic response |
| US11406563B2 (en) | 2018-07-27 | 2022-08-09 | Société des Produits Nestlé S.A. | Oral immunotherapy unit dose dispensing systems and methods |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| WO2020100024A1 (en) * | 2018-11-12 | 2020-05-22 | Murdoch Childrens Research Institute | Method and system |
| CA3123605A1 (en) | 2018-12-20 | 2020-06-25 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy dosing schedule for missed doses |
| EP3965815A4 (en) * | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| CA3162040A1 (en) * | 2019-12-23 | 2021-07-01 | Bronwyn POLLOCK | Pharmaceutical compositions |
| AU2020412960A1 (en) * | 2019-12-23 | 2022-06-16 | Prota Therapeutics Pty Ltd | Allergy treatment |
| BR112022026945A2 (pt) | 2020-07-01 | 2023-03-07 | Nestle Sa | Determinação de equipe médica para imunoterapia oral |
| WO2022089595A1 (en) * | 2020-10-30 | 2022-05-05 | Oneness Biotech Co., Ltd. | Biomarkers for ige-mediated diseases |
| JP2024509087A (ja) * | 2021-02-24 | 2024-02-29 | オールアダプト イミュノセラピューティクス，インコーポレイテッド | アレルギーの治療方法 |
| US20250342925A1 (en) * | 2022-04-15 | 2025-11-06 | Samsung Life Public Welfare Foundation | Method for providing food allergy treatment service using oral immunotherapy, computer program stored in recording medium to implement method, and system |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809767A (en) | 1969-05-12 | 1974-05-07 | Griffith Laboratories | Methods of making vegetable protein concentrates |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
| US20090111702A1 (en) | 2004-04-06 | 2009-04-30 | Mount Sinai School Of Medicine Office Of Industrial Liason | Methods of determining allergen response using microarray immunoassay techniques |
| MX2011006353A (es) | 2008-12-19 | 2011-07-13 | Merz Pharma Gmbh & Co Kgaa | Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos. |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| GB201104537D0 (en) * | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
| DE102011086048A1 (de) | 2011-04-07 | 2012-10-11 | Continental Teves Ag & Co. Ohg | Gehäuseseitige Trennschicht zur Stressentkopplung von vergossenen Elektroniken |
| WO2014159607A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
| US9492535B2 (en) * | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| US20150320706A1 (en) * | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| AU2015306683B2 (en) | 2014-08-25 | 2021-11-25 | Societe Des Produits Nestle S.A. | Egg protein formulations and methods of manufacture thereof |
| EP3568027A4 (en) | 2017-01-13 | 2020-11-11 | Aimmune Therapeutics, Inc. | WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY |
-
2018
- 2018-11-01 JP JP2020524388A patent/JP7498661B2/ja active Active
- 2018-11-01 CA CA3080601A patent/CA3080601A1/en active Pending
- 2018-11-01 US US16/178,502 patent/US11369676B2/en active Active
- 2018-11-01 MX MX2020004683A patent/MX2020004683A/es unknown
- 2018-11-01 EP EP18871949.6A patent/EP3703743A4/en active Pending
- 2018-11-01 KR KR1020207015239A patent/KR102753602B1/ko active Active
- 2018-11-01 CN CN201880071608.XA patent/CN111344010A/zh active Pending
- 2018-11-01 AU AU2018358125A patent/AU2018358125B2/en active Active
- 2018-11-01 WO PCT/US2018/058777 patent/WO2019089978A1/en not_active Ceased
-
2022
- 2022-05-24 US US17/752,639 patent/US12357688B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501763A5 (https=) | ||
| Vickery et al. | Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective | |
| Ontaneda et al. | Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives | |
| Berger et al. | Postoperative cognitive dysfunction: minding the gaps in our knowledge of a common postoperative complication in the elderly | |
| JP7498661B2 (ja) | 経口免疫療法の方法 | |
| Jacobsen et al. | Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit-the centenary of allergen specific subcutaneous immunotherapy | |
| Kugathasan et al. | Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction | |
| Elizur et al. | Oral immunotherapy in cow's milk allergic patients: course and long-term outcome according to asthma status | |
| JP7536035B2 (ja) | ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価 | |
| Lee et al. | Biphasic reactions in children undergoing oral food challenges. | |
| Ydemann et al. | Treatment of critical illness polyneuropathy and/or myopathy-a systematic review | |
| Yin et al. | Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children | |
| Trad et al. | Ebola virus disease: an update on current prevention and management strategies | |
| Komeda et al. | Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): a pediatric drug use investigation | |
| Ebner et al. | Booster immunotherapy (BIT) | |
| Keet | Recognition and management of food induced anaphylaxis | |
| Zhu et al. | Dupilumab for treatment of food-dependent, exercise-induced anaphylaxis: report of one case | |
| Barbi et al. | Adverse effects during specific oral tolerance induction: in-hospital" rush" phase | |
| Kerstjens et al. | Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group. | |
| Ide et al. | Immunological responses to a Brazilian Jiu‐Jitsu high‐intensity interval training session | |
| Parise | Travelling safely to places at high altitude-Understanding and preventing altitude illness | |
| KR20230154249A (ko) | 파킨슨 질환의 치료 | |
| Kumar et al. | Comparative evaluation of the therapeutic efficacy and safety of injected histaglobulin versus autologous serum therapy in chronic urticaria | |
| Moss et al. | Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector | |
| Pornsuriyasak et al. | Effects of oral procaterol for postinfectious cough in adults: single-Centre, randomized double-blind, placebo-controlled trial |